Background and Purpose
Because of the health emergency created by the COVID-19 virus, three COVID-19 vaccinations have been authorized by the U.S. FDA for Emergency Use Administration (EUA). The vaccine clinical trials were streamlined and essentially excluded people with a current or past diagnosis of cancer. Therefore, how people with blood cancer respond to the COVID-19 vaccinations is unknown.Read More
RYE BROOK, N.Y., April 22, 2021 /PRNewswire/ -- The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) today announced five new investments aimed at speeding the development of new and improved immunotherapies for the treatment of blood cancers. LLS has dedicated more than $100 million over the past several decades, through both grants and TAP investments, to advancing pioneering approaches that harness cellular immunotherapies to fight blood cancers.Read More
Findings from the recent King’s College London study show that three weeks after one dose of the Pfizer vaccine, an antibody response was found in 39% of solid cancer patients and just 13% of people with blood cancer, compared to 95% in healthy individuals. There was a promising report that three out of five (60%) blood cancer patients studied had an immune response after the second dose, but there were not enough blood cancer patients studied for full clinical interpretation.Read More
The Leukemia & Lymphoma Society condemns violence and discrimination against members of the Asian, Asian American, and Pacific Islander community, which has intensified because of the pandemic and misinformation about how COVID-19 spreads.
As an organization committed to scientific research, advocacy, education, and support, we must fight injustice and racism with the same urgency as we fight blood cancers. We can only accomplish our work to alleviate healthcare disparities if we fight inequity in all its forms.Read More
The Leukemia & Lymphoma Society (LLS) has heard from blood cancer patients and caregivers who are concerned about new research suggesting that mRNA-based COVID-19 vaccines may offer less protection for people with certain blood cancers.Read More
Rye Brook, NY (April 15, 2021) Every three minutes, one person in the U.S. is diagnosed with a blood cancer. But, The Leukemia & Lymphoma Society (LLS), the global leader in the fight against blood cancer, is making game-changing progress in changing this statistic. Read More
WASHINGTON, D.C., March 25, 2021 – A new report published by 30 patient organizations shows the significant risks patients face when they enroll in non-compliant and substandard health insurance products, and details ways state and federal lawmakers can help protect these vulnerable consumers.Read More
Please send all media-related inquiries and interview requests to firstname.lastname@example.org. An LLS representative will respond as soon as possible.